Rapidly dividing immune system cells

Rapidly dividing immune system cells represent a physiological state of leukocytes, primarily lymphocytes, characterized by high rates of mitosis and DNA replication (StatPearls). This biological state is essential for the adaptive immune response but is also central to the pathogenesis of autoimmune diseases, transplant rejection, and hematologic malignancies like leukemia (NIH). Therapeutic intervention typically involves the use of antimetabolites or cytotoxic drugs that interfere with DNA replication or nucleotide synthesis, thereby preventing the clonal expansion of these cells (PubChem). For example, drugs like methotrexate and mycophenolate mofetil target metabolic pathways that these rapidly dividing cells are uniquely dependent upon (PubMed). However, because these mechanisms often affect other high-turnover tissues, they are associated with significant safety concerns such as myelosuppression and gastrointestinal distress (StatPearls).

Other names

Proliferating lymphocytesActivated immune cellsDividing leukocytesMitotically active immune cells

Inhibition of DNA synthesis, interference with purine or pyrimidine metabolism, and disruption of the cell cycle to prevent clonal expansion of immune cells (StatPearls).